Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose-derived Mesenchymal Stem Cells in Multiple Sclerosis
NCT02326935Phase 1Terminated
- Sponsor
- American CryoStem Corporation
- Start
- Nov 2014
- Primary completion
- May 2018
- Modality
- Mesenchymal Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of astrostem in multiple sclerosis (MS), sponsored by American CryoStem Corporation. Primary endpoints: Standard Complication Questionnaire at 3 months, Multiple Sclerosis Impact Scale-29 at 3 months and 2 more. Started Nov 2014; status: terminated.
02
Drugs
astrostem
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02326935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326935.